A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer

By El-Rayes Bassel   Philip Philip   Sarkar Fazlul   Shields Anthony   Ferris Ann   Hess Kenneth   Kaseb Ahmad   Javle Milind   Varadhachary Gauri   Wolff Robert   Abbruzzese James  

Investigational New Drugs, Vol. 29, Iss. 4, 2011-08 ,pp. : 694-699

Springer Publishing Company

Access to resources Recommend Favorite

A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer

By Renouf Daniel  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 779-786

Springer Publishing Company

Access to resources Recommend Favorite

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

By Tsavaris Nicolas   Kosmas Christos   Skopelitis Helias   Gouveris Panagiotis   Kopteridis Petros   Loukeris Dioynissis   Sigala Frantzeska   Zorbala-Sypsa Alexandra   Felekouras Evangelos   Papalambros Efstathios  

Investigational New Drugs, Vol. 23, Iss. 4, 2005-08 ,pp. : 369-375

Springer Publishing Company

Access to resources Recommend Favorite

Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study

By Richards Donald   Kuefler Paul   Becerra Carlos   Wilfong Lalan   Gersh Robert   Boehm Kristi   Zhan Feng   Asmar Lina   Myrand Scott   Hozak Rebecca   Zhao Luping   Gill John   Mullaney Brian   Obasaju Coleman   Nicol Steven  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 144-153

Springer Publishing Company

Access to resources Recommend Favorite

Weekly Gemcitabine plus Fluorouracil-Folinic Acid Given Weekly for Two Days in Patients with Advanced Pancreatic Cancer: A Phase II Study

By Aristides Polyzos  

Clinical Drug Investigation, Vol. 24, Iss. 11, 2004-01 ,pp. : 661-670

Adis International

Access to resources Recommend Favorite